Фельден is commonly used to provide symptomatic relief and manage associated pain across several clinical domains. It is used when supportive symptom management is appropriate, particularly for persistent symptoms or those that intensify suddenly.

Symptom Relief for Inflammatory Conditions

This medication is generally used for the symptomatic management of conditions characterized by periods of heightened symptoms, such as Rheumatoid Arthritis, Osteoarthritis, and Ankylosing Spondylitis. It helps address symptom clusters that may become intense or disruptive, including persistent joint pain, swelling, and limiting stiffness that interfere with daily functioning. The drug is also applied in clinical settings involving acute or unstable symptom patterns, such as severe flare-ups of gouty arthritis or significant menstrual pain (dysmenorrhea). Used when short-term symptomatic assistance is needed, it provides support that helps ease the overall symptom burden during phases of increased distress or discomfort.

---

Quick Fact: Addresses Symptoms Related to Pain and Inflammation
Relevant for	Conditions involving persistent joint pain and tissue swelling.
Symptom Support Context	Supportive relief for chronic and acute symptomatic phases.
Supportive Aim	Helps manage stiffness that interferes with daily functioning.

Regulatory References

1. NIH MedlinePlus overview of Piroxicam

Eligibility Map: Who Can and Cannot Use Фельден (Piroxicam) — Official Regulatory Information

The eligibility to use Фельден (Piroxicam) is strictly governed by population rules defined in government regulatory labeling.

Populations for whom use is contraindicated:

• Patients with known hypersensitivity to Piroxicam or any history of allergic reactions (e.g., asthma, urticaria) after taking aspirin or other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).
• Individuals with active peptic ulcer or a history of gastrointestinal ulceration, bleeding, or perforation.
• Pregnant women starting at 30 weeks gestation and later, or patients treated for pain following Coronary Artery Bypass Graft (CABG) surgery.

Age-related eligibility rules:

• Use is primarily approved for adults (typically 18 years and older).
• Safety and efficacy are not established for the pediatric population.
• Older adults (70+ years) are classified as high-risk for serious gastrointestinal events and require close monitoring; use should be avoided over 80 years.

Condition-specific eligibility rules:

• Patients with advanced renal disease or severe heart failure must avoid use unless benefits clearly outweigh the risk of worsening the condition.
• Dose reduction must be considered for patients identified as CYP2C9 poor metabolizers due to the risk of abnormally high plasma concentrations.
• Use is not recommended for nursing mothers.

Interactions with other medicines and products

Regulatory documents establish specific interaction patterns for Piroxicam (Фельден), focusing on additive risks and metabolic pathway interference.

Pharmacodynamic and Contraindicated Combinations

• Other Systemic NSAIDs: Co-administration with other non-aspirin systemic Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) is restricted due to a documented increase in the risk of serious gastrointestinal (GI) adverse events.
• Anticoagulants and Antiplatelets: Concomitant use with oral anticoagulants (like warfarin) or antiplatelet drugs results in a pharmacodynamic enhancement of the risk of bleeding and GI ulceration.
• Antihypertensives and Diuretics: Piroxicam may officially diminish the therapeutic effect of medicines for blood pressure control, including ACE inhibitors, ARBs, and diuretics.
• Procedural Restriction: Use of Piroxicam is contraindicated in the peri-operative setting of coronary artery bypass graft (CABG) surgery.

Metabolic and Exposure Interactions

• CYP2C9 Inhibitors and Poor Metabolizers: Piroxicam's clearance is subject to inhibition by CYP2C9 inhibitors, which may lead to increased plasma concentrations. Individuals identified as CYP2C9 poor metabolizers are also at a documented risk of abnormally high systemic exposure.
• Lithium and Methotrexate: Piroxicam can officially increase the plasma concentrations and reduce the renal clearance of lithium and methotrexate, raising the risk of accumulation.

Substance and Population Notes

• Alcohol (Ethanol): Ingestion of alcohol is documented to increase the risk of developing gastric irritation and GI mucosal bleeding.
• High-Risk Patients: Co-administration with ACE inhibitors or ARBs in elderly, volume-depleted, or renally impaired patients carries a documented risk of renal function deterioration.

Modulation of the Prostaglandin Synthesis Pathway

The primary action of Piroxicam (Фельден) involves the non-selective competitive inhibition of the Cyclooxygenase (COX) enzyme system, specifically COX-1 and COX-2. This mechanism acts early in the arachidonic acid cascade, blocking the metabolic conversion of the precursor molecule and thereby preventing the synthesis of prostaglandins ( PGE2) and other prostanoids which function as signaling mediators. This decrease in prostanoid synthesis leads to the physiological consequence of reduced peripheral nociceptor sensitization and a lower concentration of signaling mediators in local microenvironments.

Modulation of Cellular Inflammatory Processes

Beyond enzyme inhibition, the drug also modulates cellular mechanisms relevant to inflammation. Piroxicam directly stabilizes lysosomal membranes within certain inflammatory cells, such as neutrophils. This stabilization limits the uncontrolled release of hydrolytic enzymes from these cellular structures. This modulation of cellular activity contributes to the drug's overall profile of affecting local inflammatory responses and resets the hypothalamic thermoregulatory center.

Фельден (Piroxicam) is officially administered via the oral route in the form of 10 mg or 20 mg capsules or tablets, and via intramuscular (IM) injection (20 mg/mL) for acute, restricted use.

Standard Dosage and Frequency

For chronic symptomatic management, the standard maintenance dose is 20 mg given once daily. An alternative regimen of 10 mg twice daily is approved, maintaining the 20 mg maximum recommended daily dose. The dosing strategy for acute flare-ups, such as gouty arthritis, involves an initial dose of 40 mg daily for the first four to six days to achieve rapid therapeutic levels.

Administration Context and Time-Course

Oral formulations must be taken with or immediately after food or a full glass of water to ensure proper administration. Due to the drug’s prolonged half-life, steady-state plasma concentrations are not reached for seven to twelve days; consequently, the full therapeutic effect should not be assessed for at least two weeks of continuous therapy. The intramuscular injection route is strictly restricted for use only when oral administration is not feasible and is limited to a short course, typically not exceeding two to three days.

Population-Specific Use

Official instructions require starting therapy at the low end of the dosing range for older adults. Furthermore, dose reduction must be considered in patients with impaired renal function and in individuals known to be CYP2C9 poor metabolizers due to decreased drug clearance. The overall protocol mandates using the lowest effective dosage for the shortest duration necessary, with long-term use requiring periodic re-evaluation.

Research Evidence / Overview of Studies for Фельден

Evidence for use in Osteoarthritis (OA) and Rheumatoid Arthritis (RA)

Фельден (Piroxicam) was studied for conditions characterized by fluctuating or episodic manifestations, particularly in adults with Osteoarthritis (OA) and Rheumatoid Arthritis (RA). Research primarily consists of Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. Studies primarily focused on outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level, using patient-reported outcomes describing perceived discomfort to assess short-term changes.

Trials and systematic reviews report patterns observed in the studies related to changes measured during the study period, including pain intensity and functional measures like joint mobility. Findings describe patterns observed in the studies related to outcomes linked to inflammatory or irritative states, which helps contextualize how patients reported their experience during the trials. However, the existing evidence is largely focused on short to intermediate-term relief, with follow-up durations were limited in many core RCTs.

Evidence for Acute Inflammatory Conditions

Research has also explored the role of Фельден in managing conditions associated with acute or disruptive episodes, such as Ankylosing Spondylitis (AS) and Acute Gouty Arthritis flare-ups.

For AS, controlled trials have examined outcomes related to spinal pain, duration of morning stiffness, and changes in overall mobility. For Acute Gouty Arthritis, studies focused on episodes where symptoms become more noticeable, specifically measuring the speed and magnitude of change in pain and the evolution of local inflammatory states over a very short duration, typically less than one week. Findings show patterns related to acute changes in symptoms during the study periods. For both AS and acute gout, the sample sizes were modest in many of the trials, and evidence quality varies across studies.

What is Still Uncertain about the Research Base

The research provides context on symptomatic change across several inflammatory conditions, but certain aspects remain areas of uncertainty in the evidence landscape:

• Comparative evidence is lacking for long-term functional and pain outcomes when comparing Фельден against some of the newest or most recently developed treatments.
• The evidence structure is heavily geared towards short-term relief, meaning there is limited information for long-term outcomes regarding the sustained change in outcomes reflecting daily functioning or activity level.

Key Studies & References

1. Efficacy and safety of piroxicam revisited: a global meta-analysis of randomised clinical trials

Common questions about Фельден (FAQ)

---

Q: How long does it take for Piroxicam to start reducing my pain after I take a dose?

Official product information suggests initial pain relief for conditions like arthritis may be noted after approximately one week of use. However, due to the medicine's prolonged effect in the body, the full therapeutic effect is typically assessed after two weeks of continuous therapy.

---

Q: What are the signs of a serious gastrointestinal bleeding side effect?

Regulatory warnings highlight the potential for serious gastrointestinal events. Signs of bleeding that have been noted include bloody or tarry stools, or vomiting blood or material that looks like coffee grounds. If these signs are observed, contact a healthcare professional right away.

---

Q: Which foods or supplements should I avoid when taking this medicine?

Regulatory documents state that alcohol (ethanol) should be avoided while using this medicine, as it can significantly increase the risk of stomach bleeding and irritation. No other specific foods or supplements are typically highlighted in the labeling as strictly prohibited, although the medicine should be taken with food or water.

---

Q: How does Piroxicam affect the liver, and should I get blood tests?

Official prescribing information states that this medicine can sometimes cause elevated liver enzymes. In rare cases, more severe liver problems have been reported. Official labeling advises that therapy should be discontinued if liver enzyme abnormalities persist or worsen, or if signs of liver disease appear.

---

Q: If I forget to take my Piroxicam dose, what should I do?

Product information states that if a dose is missed, it can be taken as soon as the patient remembers. However, if it is close to the time of the next scheduled dose, the missed dose should be skipped, and the regular schedule should be continued. A double dose should not be taken to compensate for a missed dose.

---

Q: Can I get Piroxicam as a generic drug, and is it cheaper?

Yes, Piroxicam is available as a generic drug, which contains the same active ingredient as the brand-name product. The generic version is often available at a lower cost compared to the brand-name product.

How to Store and Dispose of Feldene (Piroxicam)

The official labeled instructions for Feldene (piroxicam) strictly govern storage and disposal to maintain product stability.

Storage Requirements

Feldene must be stored at Controlled Room Temperature, which is typically 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C. The medicine must be actively protected from light and stored in a dry place to prevent moisture exposure.

To ensure safety, the product must be kept in its original container, tightly closed, and stored out of the sight and reach of children.

Disposal

Disposal of unused or expired Feldene must be carried out in accordance with all local and national regulations. Regulatory bodies generally advise against flushing the medicine down the toilet or pouring it down a sink. The preferred method is typically taking the product to a designated drug take-back location.